Giuseppe Ciaramella - 06 Nov 2024 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role
President
Signature
By: /s/ Christine Bellon, Attorney-in-fact
Issuer symbol
BEAM
Transactions as of
06 Nov 2024
Net transactions value
-$1,347,050
Form type
4
Filing time
08 Nov 2024, 16:10:06 UTC
Previous filing
16 Oct 2024
Next filing
19 Dec 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BEAM Common Stock Sale $1,347,050 -51,110 -32% $26.36 109,150 06 Nov 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $26.00 to $26.98, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.